Paula F. Ypma

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 377 citations · Full text

Hematological Malignancy, Transplantation, Marrow Transplantation +9

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

Hartmut Goldschmidt, H M Lokhorst, E K et al. · Leukemia · 2017 · 197 citations · Full text

Hematological Malignancy, Oncology, Hematology +7

von Willebrand disease and aging: an evolving phenotype

Yvonne Sanders, M.A. Giezenaar, Britta A. P. Laros‐van Gorkom et al. · Journal of Thrombosis and Haemostasis · 2014 · 105 citations · Full text

Disease Mechanism, Pathology, Von Willebrand Disease

Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial

Ingrid M. Bistervels, Andréa Buchmuller, Hanke M.G. Wiegers et al. · The Lancet · 2022 · 93 citations · Full text

Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease

Eva M. de Wee, H.M. Knol, Evelien P. Mauser‐Bunschoten et al. · Thrombosis and Haemostasis · 2011 · 92 citations · Full text